ProMetic and FDA Close Successful Pre-IND Meeting for PBI-4050 for Idiopathic Pulmonary Fibrosis
ProMetic Life Sciences, Inc., a biopharmaceutical corporation active in the development of novel therapeutic products targeting unmet medical needs in several fields, including fibrosis, is pleased to announce it recently concluded a successful Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational anti-fibrotic…